The MFDS supports ₩25.6 billion for COVID-19

Budget ₩604.4 billion in 2021, up 8.1% from this year

The MFDS has established a budget of ₩25.6 billion next year to support the commercialization of COVID-19 vaccines and K-quarantine products.

 

The MFDS announced on the 2nd that the government budget for 2021 has increased by ₩45.2 billion (8.1%) from ₩559.2 billion this year to a total of ₩604.4 billion.

 

The budget for 2021 includes that ▲ securing food safety for consumers to become healthier ▲ strengthening the management of medicines and medical devices that patients can rest assured ▲ building a preemptive safety foundation for the future.

 

In particular, it announced that it will provide a solid foundation for safety against the post-coronavirus by supporting domestic development, commercialization, and rapid supply of vaccines with high dependence on imports, and to closely manage hygiene and nutrition to small daycare centers that do not have the obligation to hire nutritionists to ensure the safety of children's meals.

 

In detail, a drug design-based quality by design (QbD) model was developed (₩3.2→5.2 billion) for the establishment of a pharmaceutical smart factory, and the 'Advanced Biopharmaceutical Regulatory Science Center' was operated (₩900 million) and a long-term tracking investigation system (₩2.9 billion).

 

In addition, the MFDS explained that it will expand support for the commercialization of innovative medical devices and establish a management system (₩100 million →₩1.2 billion) and technical support for the commercialization of in vitro diagnostic medical devices (₩400 miliion → ₩900 million).

 

In addition, it plans to implement patient-centered safety management of medical products by preparing the basis for evaluation of next-generation medical products (R&D, ₩4.1 billion) using big data produced in medical fields.

 

The MFDS added that it will reinforce national testing equipment and built a BSL3 laboratory (₩700 million→₩4.5 billion) to quickly supply COVID-19 related vaccine and treatment in Korea and will expand support for the operation of Hwasun 'Vaccine Safety Technology Support Center' (2→₩5.8 billion) to improve the domestic vaccine self-sufficiency rate.

 

In addition, to support the development of K-quarantine products, a laboratory dedicated to the quality and performance of in vitro diagnostic medical devices (₩1 billion) was installed, and research on approval/examination evaluation technology for quarantine products such as COVID-19 treatments, vaccines, and masks (R&D, ₩4.4→ 6.9 billion), and it has announced that it will start a business (R&D, ₩3.1 billion) that will lead the biohealth industry.

 

The MFDS announced that when the government budget for 2021 is finalized in December of this year through the parliamentary deliberation process, it will promptly and actively promote next year's major projects, including national tasks, as a vision for 'safe food and medicine, healthy citizens'.